- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology. 2017 In Process GET IT
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
Times cited: 9
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
The New England journal of medicine.
Times cited: 604
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
Times cited: 95